Clinical Trials Logo

Uncomplicated Falciparum Malaria clinical trials

View clinical trials related to Uncomplicated Falciparum Malaria.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT00902811 Recruiting - Clinical trials for Uncomplicated Falciparum Malaria

Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria

ACT
Start date: December 2008
Phase: Phase 4
Study type: Interventional

Antimalarial drug resistance is increasing nearly everywhere in the tropical world, confounding global attempts to "Roll Back Malaria." South East Asia has the most resistant malaria parasites in the world. This has limited the options for treatment in this region. Artemisinin-based combination therapy is now the recommended treatment for uncomplicated falciparum malaria. The success of this policy change in practice will depend on the efficacy of the components of the combination used, the population coverage achieved, high levels of adherence to treatment, low cost of the drugs, and preferably the drugs in a combination treatment should be formulated in a single tablet, to prevent one drug being taken without the partner drug. Until recently there were only two artemisinin-based fixed combinations available, artemether-lumefantrine and dihydroartemisinin-piperaquine; and only the former has international registration. More fixed combinations are needed urgently.